These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 16632010)

  • 61. Calcimimetic agents: review and perspectives.
    Ureña P; Frazão JM
    Kidney Int Suppl; 2003 Jun; (85):S91-6. PubMed ID: 12753275
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Parathyroidectomy for secondary hyperparathyroidism in the era of calcimimetics.
    Tominaga Y; Matsuoka S; Uno N; Sato T
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S21-6. PubMed ID: 19032523
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cinacalcet and Clinical Outcomes in Dialysis.
    Komaba H; Fukagawa M
    Semin Dial; 2015; 28(6):594-603. PubMed ID: 26265359
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Evolution of secondary hyperparathyroidism after kidney transplantation in patients receiving cinacalcet on dialysis.
    Torregrosa JV; Bergua C; Martinez de Osaba MJ; Oppenheimer F; Campistol JM
    Transplant Proc; 2009; 41(6):2396-8. PubMed ID: 19715931
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cinacalcet hydrochloride for the treatment of hyperparathyroidism.
    Verheyen N; Pilz S; Eller K; Kienreich K; Fahrleitner-Pammer A; Pieske B; Ritz E; Tomaschitz A
    Expert Opin Pharmacother; 2013 Apr; 14(6):793-806. PubMed ID: 23452174
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The calcium receptor and calcimimetics.
    Wada M; Nagano N; Nemeth EF
    Curr Opin Nephrol Hypertens; 1999 Jul; 8(4):429-33. PubMed ID: 10491737
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The impact of calcimimetic agents on the use of different classes of phosphate binders: results of recent clinical trials.
    Szczech LA
    Kidney Int Suppl; 2004 Sep; (90):S46-8. PubMed ID: 15296507
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Use of ultrasound to assess the response to therapy for secondary hyperparathyroidism.
    Meola M; Petrucci I; Colombini E; Barsotti G
    Am J Kidney Dis; 2011 Sep; 58(3):485-91. PubMed ID: 21715073
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
    Wilkie M; Pontoriero G; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Zani VJ; Carter D; Messa P
    Nephron Clin Pract; 2009; 112(1):c41-50. PubMed ID: 19365139
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Short-term use of cinacalcet in children on regular hemodialysis.
    Youssef D
    Arab J Nephrol Transplant; 2012 Jan; 5(1):51-3. PubMed ID: 22283867
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Calcimimetics and hyperparathyroidism.
    Krebs LJ
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1080-5. PubMed ID: 15535429
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of calcimimetics on long-term outcomes in dialysis patients: literature review and Bayesian meta-analysis.
    Lozano-Ortega G; Waser N; Bensink ME; Goring S; Bennett H; Block GA; Chertow GM; Trotman ML; Cooper K; Levy AR; Belozeroff V
    J Comp Eff Res; 2018 Jul; 7(7):693-707. PubMed ID: 29762046
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cinacalcet: AMG 073, Calcimimetics--Amgen/NPS Pharmaceuticals, KRN 1493, NPS 1493.
    Drugs R D; 2003; 4(6):349-51. PubMed ID: 14584963
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats.
    Chin JI; Miller SC; Wada M; Nagano N; Nemeth EF; Fox J
    J Am Soc Nephrol; 2000 May; 11(5):903-911. PubMed ID: 10770968
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cinacalcet hydrochloride: calcimimetic for the treatment of hyperparathyroidism.
    Locatelli F; Pontoriero G; Limardo M; Tentori F
    Expert Rev Endocrinol Metab; 2006 Mar; 1(2):167-179. PubMed ID: 30754140
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Calcimimetic agents and secondary hyperparathyroidism: treatment and prevention.
    Goodman WG
    Nephrol Dial Transplant; 2002 Feb; 17(2):204-7. PubMed ID: 11812865
    [No Abstract]   [Full Text] [Related]  

  • 78. Calcimimetic agents and the calcium-sensing receptor.
    Coburn JW; Maung HM
    Curr Opin Nephrol Hypertens; 2000 Mar; 9(2):123-32. PubMed ID: 10757216
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Regression of parathyroid hyperplasia by calcimimetics--fact or illusion?
    Komaba H; Fukagawa M
    Nephrol Dial Transplant; 2009 Mar; 24(3):707-9. PubMed ID: 19103739
    [No Abstract]   [Full Text] [Related]  

  • 80. Secondary hyperparathyroidism disease stabilization following calcimimetic therapy.
    Frazão J; Rodriguez M
    NDT Plus; 2008 Jan; 1(Suppl 1):i12-i17. PubMed ID: 25983950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.